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Abstract

HMG-COAREDUCTASE INHIBITORS ACT SYNERGISTICALLY WITH UCN-0 1
THROUGH RAS INHIBITION
By Payal Khanna, M. S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2005
Major Director: Steven Grant, M.D.
Hematology Oncology

The primary objective of this study is to elucidate the mechanism by which the reagent
UCN-01 induces apoptosis when administered to leukemia cells along with HmG-CoA
reductase inhibitors, mainly the statins. In this study, we demonstrated that exposure of
leukemia cell lines to lovastatin (20 uM, 18 hours) and UCN-01 (1 00 nM, 18 hours)
resulted in mitochondria1 dysfunction, procaspase 3 and 9 cleavage, and P A W degradation
along with marked cytochrome C release and apoptosis. Although similar molecular
mechanisms have not yet been confirmed in other cancers, our hypothesis holds that
enhanced apoptotic effects of UCN-01 are due in part to lovastatin's ability to block
formation of geranylgeranylpyrophosphateand farnesylpyrophosphateby interfering with
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the rate-limiting step of the mevalonate pathway. Geranylgeranylpyrophosphate and
farnesylpyrophosphate induce post-translational modifications in RAS that anchor the
protein to the cell membrane so that it acts as a signal transducer to the nucleus, promoting
cell proliferation.

INTRODUCTION
1.1 Mechanisms of Cancer Proliferation and Survival
Hematopoietic cells originate from common stem cells, which have pluripotent
function and give rise to two types of progenitors, B lymphocytes and T lymphocytes or
leukocytes and erythrocytes. The process of continual hematopoietic proliferation and
differentiation of cells is balanced physiologically through apoptotic or mechanisms that
induce cell death. Cancers including leukemia and multiple myeloma are due in part to
errors existing in genetic code within immature hematopoietic cells resulting in abnormal
expression of proteins and evasion of cell death, hindering cell maturity. Most
chemotherapies target the specific pathways that initiate inappropriate protein expression
in cancer cells in an attempt to induce apoptosis.

1.2 Cell Cycle
Several transforming mutations involving RAS/RAF/MEKfERKand PI3WAKT
pathways have been linked to cell cycle arrest or inappropriate activation of CDKs thus it
is important to study the underlying mechanisms that control the transition of the cell from
one stage to the next. Cells proceed through five phases: the S, GI, G2, M, and Go. In the
Go phase, terminally differentiated cells withdraw from the cycle. Once extracellular
signals commit the cells to entry in the G1 phase, RNA and protein synthesis prepare the
cell to divide, cells passing a restriction point are therefore committed to entry into the S
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phase. The transition of the GI to S phase is tightly controlled by protein kinases that
change their conformation in response to extracellular signals. Protein kinases
phosphorylate specific proteins at specific times to coordinate metabolic activities and
initiate orderly cell division, consisting of a regulatory (cyclin) and a catalytic (CDK)
subunit. When cyclin binds, the catalytic site opens and activity of the CDK increases
10,000 fold. There are several forms of cyclinlCDK complexes corresponding to the
transition of each stage of the cell cycle. During the first phase of the cycle, the G1 phase,
cyclin D forms a complex with the CDK4 or CDK 6 subunit. Once cyclin D associates
with CDK4 or 6, phosphotase Cdc25C acts as a checkpoint control to DNA damage in the

S phase. This CDK complex then phosphorylates the protein Rb, which is a tumor
suppressor protein involved in sequestration of E2F transcription factors that prevent
activation of genes critical for DNA synthesis during the S phase. Once Rb is
phosphorylated, E2F transcription factors are expressed, allowing DNA synthesis during
the S phase. In several studies, overexpression of cyclin D or loss of Rb function has been
linked to tumors. Late in GI, cyclin E forms a complex with CDK2 and this marks the
entry of the cell into the S phase. The synthesis of cyclin E promotes the synthesis of
additional E2F transcription factors, thus, this process acts a positive feedback loop. Once
in the S phase, cyclin E is degraded and CDK2 associates with cyclin A and B, allowing
the cell to enter mitosis and undergo cell division. Progress through mitosis requires that
there is timed activation and then destruction of cyclins A and B, which activate CDK2.
Continual synthesis and degradation of cyclins allow their counterpart, CDKs to become
activated at appropriate times, followed by inactivation.

As illustrated in Figure 1.1, production of cyclins followed by their degradation
allows for transitioning of the cell from one phase to the next, while CDK levels remain
fairly constant. These CDKs are tightly controlled and depend on association with cyclins
followed by inactivation of CDKs through action of anti-growth factors and CDK
inhibitors belonging to either Cip/Kip family or CDK4 inhibitors. Members of the Kip
family include p21, p27, and p57 and may inhibit CDK 2,4, and 6.
Figure 1.1 Cyclin Synthesis and Degradation (18)

Cyclin Expression Fluctuates
throughout a Cell Cycle
Mitogen Stimulation

Figure 1.2 illustrates the corresponding cyclin-CDK complexes that regulate the
cell cycle. In several tumors, inappropriate activation of CDKs has caused cell proliferation
in the absence of extracellular signals such as hormones. There have been several synthetic
inhibitors created that modulate CDK activity to induce apoptosis, causing cell cycle arrest
in an attempt to counteract continual cell proliferation brought about by cancer. Most of
these inhibitors act via interaction with the ATP site of cdk's, these inhibitors include
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UCN-01, flavopiridol, and roscovitine. In this study, the major CDK inhibitor was 7hydroxystaurosporine, an analog of UCN-01 .
Figure 1.2 Cell Cycle Regulation (18)

cdk2
cyclin A

1.3 UCN-Ol(7-Hydroxystaurosporine)

7-hydroxystaurosporine has been classified as a specific analogue of staurosporine
that specifically targets protein kinases (24). UCN-01 specifically inhibits protein kinase C
isoenzymes, specifically those isoforms that are calcium dependant. The reagent has a
hydroxyl group at the C-7 position of the indolocarbazolo moiety with the following
structure.

Figure 1.3: Chemical Structure: Staurosporine (28)

Although it is apparent in some tumors that UCN-01 acts via targeting of PKC enzymes;
other tumors treated with UCN-0 1 indicate an alternate mechanism of action (12). One
theory is that UCN-01 induces inhibition of CDKs at high concentrations in vitro,while SG1 arrest was observed at lower concentrations. In the most recent studies on the effects of
UCN-01 on cell cycle control, upregulation of the protein p21 was observed, which as
mentioned previously is involved in deactivation of CDKs and subsequent cell cycle arrest.
Since p21 has similar promoter regions to those existing in the proto-oncogene protein

RAS, which activates p21, scientists have studied the effects of UCN-01 on other kinases
activated by the protein RAS including MEWERK have been investigated.
Previously, it has been found that at concentrations 2 100 nM, UCN-01
significantly increases ERK activity and similar concentrations were found to increase
activation of MAPK, another pathway regulated by RAS. Thus, the increased activity of
p21 is due to increased activation of MEWERK and MAPK leading to observed cell cycle
arrest. Although these studies aid understanding of the mechanism involved in apoptosis
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when cells are exposed to UCN-01 alone, the apoptotic effects are minimal. In this study,
UCN-0 1 was used at lower concentrations (100- 150 nM) in combination with other
inhibitors. In our studies, it was discovered that UCN-01 in combination with
famesyltransferase inhibitors (LY744), caused G2/M abrogation, while interfering with
UCN-0 1 induced activation of the MEKERK pathway.

1.4 Mevalonate Pathway
In the past, statins have mainly been involved in control of cholesterol where their
mechanism of action has been to block an essential component of the mevalonate pathway
(18). Here, the rate-limiting step of the pathway is conversion of HMG-CoA to
mevalonate, which then leads to products, which have various functions within .the cell.
The products contain isoprene units a d include GGPP (geranylgeranyl pyrophosphate),
FPP (famesyl pyrophosphate), and cholesterol. Geranylgeranyl and farnesyl transferases
use the substrates, GGPP and FPP to perform post-translational modifications to GTPbinding proteins so that they may function, these proteins include RAS and other proteins
belonging to families Rho, Rac, etc. (2). For RAS to act as a signal transducer the protein
must be localized to the cytosolic face of the membrane, which occurs by attaching
hydrocarbon moieties to the existing protein. In this case, RAS is anchored to the
membrane by two such moieties, either farnesyl or geranylgeranyl hydrocarbons. The bond
between the famesyl or geranylgeranyl group and RAS protein is a thioester linkage,
which is formed with the cysteine group close to the carboxyl terminus of the protein and
the hydrogen on the farnesyl or geranylgeranyl moiety. Following modification of RAS,
the protein undergoes proteolysis in which three of the terminal residues of the protein are
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removed and the carboxy terminus is methylated. The transfer of the farnesyl moiety
required for the above reaction is catalyzed by the enzyme famesyltransferase, which
interacts with the substrates produced by the mevalonate pathway, FPP
(famesylpyrophosphate) and GGPP (geranylgeranylpyrophosphate).As previously
reported inhibition of farnesyltransferase inhibits localization of the RAS protein to the cell
membrane, and subsequent activation of downstream signaling pathways. The lethality of
farnesyl transferase inhibitors were enhanced when combined with UCN-0 1. However,
RAS isoforms may still overcome the effects of these inhibitors since geranylgeranyl
moieties also bind particular members of the RAS family, including HRAS and NRAS to
the cell membrane. As mentioned above, blocking RAS may dramatically enhance the
effects of the CDK inhibitor, UCN-01 (4). One of the theoretical advantages of using
HMG- CoA reductase inhibitors is the tolerance exhibited by patients of side-effects and
decreases in the amount of FPP and GGPP produced, which are required for
farnesyltransferaseto function and to modify RAS. Generally, there are four different
forms of statins. Fluvastatin and atorvastatin are synthetically derived whereas simvastatin
and lovastatin are fungal derivatives (2). In this study, we are primarily concerned with
three forms of the drug: Lovastatin, simvastatin, and fluvastatin and their actions when
combined with UCN-0 1.

The RASRAFIMEWERK pathway is often referred to the MAP kinase pathway or
mitogen-activated protein kinase. The pathway is stimulated by a variety of factors

including activation of growth factors, cytokines, and mitogens responsible for cell
division and induction of mitosis initiated by factors in the extracellular medium. In
cancer, the MEWERK pathway is activated by RAS in the absence of growth factors or
hormones, RAS subsequently promotes the translocation of RAF-1 from the cytosol to the
cell membrane, and RAF is then activated by phosphorylatioii and dephosphorylation.
RAS is a small GTP-binding protein that is activated by binding to GTPase activating
proteins and guanine nucleotide exchange factors. RAS will cycle between the active form,
which is bound to GTP and the inactive state, bound to GDP for short periods of time. In
cancers, RAS bound to GTP is hydrolyzed in its active state for an abnormally long period
of time accumulating growth-promoting signals sent to the nucleus in the absence of
growth factors or hormones, in turn, activating the MAPKinase cascade described later in
this section. There are several family members of RAS protein including HRAS, KRAS,
and NRAS. The major isoforrns found in almost 30 percent of cancers include KRAS and
NRAS. RAS not only activates RAF-1 and the MEWERK kinases, it is the major regulator
of the survival pathway, PI3WAKT.

Figure 1.4 RAS GTP-Binding Protein (34)

Raf activation
by phosphorylation
and dephosphorylatlon
of rnultlple SIT & Y
residues

Translocation

1.6 P13KfAKT Pathway
The PI3WAKT survival pathway is one of several pathways involved in cell cycle
regulation as mentioned previously. Specifically, PI3WAKT is responsible for
phosphorylation of T145 and S146 near the carboxyl terminus of p21 leading to activation
of CDK and DNA synthesis and an increase in cell proliferation (3).
The PI3WAKT pathway is activated via cytokine activity for specific receptors that
activate PI3 Kinase. The exact mechanism, by which PI3WAKT is activated, occurs when
PI3K is recruited to the plasma membrane and is phosphorylated at Thr308 by PDKl and
at Ser473 by PDK2. PP2A is a serinelthreonine-specific phosphatase that has been shown
to inhibit PI3WAKT kinase activity. Thus, PDKlPDK2-mediated phosphorylation at both
sites and PP2A-mediated dephosphorylation must work in conjunction to mediate the
PI3WAKT kinase activity in vivo (3). PI3WAKT then mediates several cellular responses
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such as glucose uptake and several downstream anti-apoptotic proteins including those
involved in the mitochondria1 pathway such as Bcl-xl and Bcl-2. The following Figure
illustrates several mechanisms of survival for the PI3IUAKT pathway.

Figure 1.5 Multiple Mechanisms of Cell Survival Regulation by PI3K/AKT/PKB (3)
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Another mechanism by which PI3KIAKT suppresses apoptosis is through
inhibition of apoptotic proteins belonging to the caspase family of cytosolic proteases (5).
Reports indicate that suppressing the PI3IUAKT pathway with PI3 Kinase inhibitors such
as LY294002 (farnesyltransferase inhibitors) synergistically enhances the cytotoxic effects
of anticancer drugs such as UCN-01.
1.7 Crosstalk Between RAS/RAF/MEK/ERK and PI3WAKT
Although RAS regulates several pathways including PUIUAKT, ERK 112, and the
Ral GDS pathways, recently it has been found that crosstalk between PI3WAKT and RAF
may occur since PI3KlAKT can directly phosphorylate RAF isoforms, however these
effects depend on the cell type and differentiation process. The first indication of possible

crosstalk between the pathways was evident when inhibition of PI3WAKT was shown to
cause a marked decrease in the amount of expression of p-ERK. In previous studies it has
been demonstrated that farnesyltransferase inhibitors such as LY294002 that inhibit
PI3WAKT also induce expression of B-RAF. Such findings warrant further study as to the
exact interaction between the PI3WAKT and RAF pathway.
Figure 1.6 PI3KlAKT Pathway and Downstream Targets of RAS
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1.8 Cell Death
Although there are several pathways which promote cell survival, these
mechanisms must be balanced physiologically through apoptosis or cell death. Cell death
occurs via two mechanisms: necrosis or apoptosis. Necrosis is a pathological process of

cell death in living organism with failure of membrane integrity. The cell membrane and
membranous structures within the cell become permeable as opposed to their normal
physiological state. A number of toxic chemicals or physical events can cause necrosis
including toxins, radiation, heat, trauma, or lack of oxygen. This process follows cell
injury and the resulting dead cells induce an inflammatory response. Necrosis is
distinguished from apoptosis in that apoptotic cell death results from energy dependent,
metabolically active, endogenous cellular processes where membrane integrity is
maintained.
The induction of apoptosis generally follows one of the two related biochemical
pathways, either extrinsic or intrinsic. The extrinsic pathway is initiated by the cell-surface
molecules belonging to the tumor necrosis factor (TNF) family of receptors (Fas[DR2],
DcR3) and their respective ligands.
Typically, receptors belonging to the TNF form what is known as a death-inducing
signal complex or DISC when paired with their respective ligands. Directly following
formation of the complex, caspase 8 and caspase 10 proteins are activated, which activate
effector proteins caspase 3 , 6 , and 7 downstream. Caspases are cytosolic proteases that
participate in apoptosis when there is a signal from .the receptor. All caspases are
synthesized as inactive proenzymes and all have a critical cys residue at the active site.
The Fas receptor, a member of the TNF fanlily, induces apoptosis via a mechanism
similar to that mentioned above. Apoptotic response is initiated when binding of a cluster
of Fas receptors at the plasma membrane results in the recruitment of cytosolic protein,
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FADD and formation of the pro-caspase 8 complex. High concentrations of the cytosolic
proteasome, pro-caspase 8 results in its autocatalysis or self-activation; activated caspase 8
cleaves effector, pro-caspase 3, which then undergoes autocatalysis to form active caspase

3, a principle effector caspase of apoptosis.
One area of interest in cancer research has been the TNF-related apoptosis-induced
ligand (TRAIL) and its receptor, which has shown great promise as an anticancer reagent.
TRAIL derivatives have been shown to induce apoptosis in tumor cells, while rarely
inducing apoptotic responses in non-transformed cells. However, the exact molecular
mechanism is not well understood. In contrast to Fas, TRAIL expression has been found in
numerous tissues including the spleen, thymus, and ovary, but is absent in the brain (20).
There are structural similarities between TRAIL and other TNF receptors; both are type I1
transmembrane proteins expressed on the cell surface. Studies indicate that TNF receptors
contain a specific group of molecules on the receptor that are responsible for inducing
apoptosis; these four molecules include TNFR1, CD95, DR3, and CAR1. Each of these
molecules contain a "death domain", an 80 amino acid cytoplasmic motif, which form a
complex with the "death domain" on the ligand to activate the caspase cascade and induce
apoptosis. However, experimentation indicates that receptors lacking this domain still
retain the ability to mediate apoptosis in T-cells, indicating a more complex mechanism
which warrants further molecular studies to elucidate the exact mechanism.
The other major signaling pathway is the intrinsic pathway also known as the
mitochondrial pathway and is activated via mitochondrial membrane damage and may be
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triggered from within the cell as opposed to the ligand-receptor system involved in the
extrinsic pathway. Apoptosis through this mechanism is detected through release of a
carrier protein, cytochrome C, from damaged mitochondria that binds a protein, Apafl.
This cascade of events initiates caspase 9 that activates effector caspase 3. A delicate
balance exists in which apoptotic proteins such as SMACIDIABLO and OmilHtrA2, which
are released from the mitochondria, may inhibit the action of anti-apoptotic proteins such
as Bcl-2 and XIAP. The common protein that links the extrinsic and intrinsic pathways is
caspase 3 whereas several anti-apoptotic proteins such as XIAP target effector caspase 3
and 7, preventing apoptosis.
In summary, several major pathways exist that promote cell survival including
PI3WAKT and MEWERK, both of which are activated by the protein RAS. These
pathways are complex and influence cell cycle activity. In addition, these survival
pathways influence apoptotic responses brought about by the caspase cascade, which may
be triggered within the cell or via the extrinsic pathway. In this study, the PKC and Chkl
inhibitor UCN-0 1 was administered at low concentrations (100- 150 nM) in conjunction
with HMG-CoA reductase inhibitors in an attempt to induce dramatic apoptosis in
leukemia cells lines and define the exact molecular mechanism involved in this response.

Materials and Methods
2.1 Cell CultureMaintenance
Human Cell Lines: 8226/Sensitive, l R M.M., U266, U937, and Jurkat are multiple
myeloma-sensitive, multiple myeloma, histiocytic lymphoma, acute promyelocytic
leukemia, and acute T-cell lines, respectively obtained from American Type Culture
Collection (Rockville, MD). Cells were maintained in 1640 RPMI Gibco medium
containing 2mM C5HI0N2O3
(L-glutamine), 2 grams NaHC03, 10 ug/ml of penicillin, 1
mM C3H3Na03,100 UM MEM nonessential amino acids, and 100 ug/n-11 streptomycin
supplied by Gibco in powder form and dissolved in 1 liter ultrapure water. The pH of the
resulting medium was adjusted to 7.25 using NaOH or HC1 according to readings from an
Omega pH meter. The medium was sterilized using vacuum filtration through a 0.22 p
filter unit from Pall (Bridgeport, NJ). The bottles of medium were stored at 4OC. Prior to
use medium was supplemented with 50 ml of FBS (fetal bovine serum). Cells were
incubated in a Greiner T-25 cm2 flask from ISC Bioexpress in a humidified incubator at
37°C and 5% C02. Once cells were obtained from American Culture Collection, the vial of
cells was thawed and cultured (free-floating) in approximately 10 ml of medium for
approximately 2-3 days. Once the cells reached a density of approximately 3 - 5 x 1o5
cells/ml, a volume of 0.5 ml cells were taken from the T-25 cm2flask and placed in 10-12,
1 ml cryovials containing 0.5 ml Cryo solution (Sigma-Aldrich), were frozen and stored in
a liquid nitrogen tank. Cells stored in the nitrogen cryogenic storage vessel were used as
needed for experimentation. One cryovial containing cells was thawed and washed 2-3
times in 1 ml of Gibco medium to remove DMSO (see above for contents). Cells
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resuspended in 1 ml of medium were added to a T-25 cm2 flask already containing
approximately 10 ml of Gibco medium. Cells were incubated starting from passage
number 3 to 60, in a humidified incubator at 37OC and 5% C02.For these cell lines no
additional drugs or reagents were added when maintaining cell culture.

2.2 Determination of Cell Density
In order to maintain the cell density between 3 - 5 x 10' cells/ml, a coulter 2 2
particle counter from Beckman Coulter (Fullerton, CA) was used to determine the density
of cells in 1 ml of fluid. The coulter counts the amount of particles passing through the
aperture based on the particle size, which is 6 um to 8 um for cells. Smaller cell sizes
indicate shrinkage, fragmentation and corresponding cell death. To determine the cell
density, a 500 uL vol~uneof each cell line maintained was obtained from the flask of
growing cells and diluted in 1 ml of conductive fluid obtained from Beckman Coulter. The
dilution was thoroughly mixed and then passed through a cylindrical aperture on the
coulter 22 particle counter from Beckrnan Coulter (Fullerton, CA) that modulates
inipedance of two electrodes positioned on either side of the apparatus every time a particle
passes through the aperture. As each particle passes through the aperture, the circuit is
interrupted and an electrical pulse is sent through the circuit, in this case the particles
passing through the aperture are cells. The number of electrical pulses corresponds to the
number of cells and this number is then illustrated as a peaked curve on a liquid crystal
display along with a numerical value on the bottom of the display. This value indicates to
the user the number of cells in 1 ml of conductive fluid or concentration of cells. In this
case, the range of particle sizes may be specified by the user so that the window displays

particles that range in size from 6um to 8 um, which are the typical sizes for living
myeloma and leukemia cell lines. To assess cell viability or for a more precise indication
of cell viability trypan blue analysis is used in cases where inconsistent cell growth is
indicated or there is discoloration of the medium during cell culture.

2.3 Cell Viability
Trypan blue is one method by which cell viability may be evaluated using a system
of scoring of four separate fields on a prepared hemocytometer (Sigma -Aldrich). First 100
uL of cells were taken from the T-25 cm2 flask and placed in a 0.5 ml microfuge tubes.
Then 100 uL of 0.4% trypan blue solution (Sigma-Aldrich)was resuspended in the
microfuge tube. The suspension of cells and trypan blue stain was then injected into the
hemocytometer (Sigma Aldrich). Cells in all four fields were counted and the number of
cells that lacked stain was determined accordingly. Living cells would lack stain since their
membranes are in tact, whereas cells with blue stain are damaged due to incorporation of
the stain into the cell because of membrane damage.

2.4 DNA Amplification and Purification
DNA purification is used so that DNA may efficiently be transfected in eukaryotic
cells. DNA HRas plasmid was ordered from Upstate Biotechnologies and propagated in a
DH1 e-coli host strain. The bacterial colonies were grown in a 1.5 % prepared agar plate
(agar fkom Invitrogen) with 50 ug/ml of ampicillan. Once bacterial colonies were visible, a
single colony was picked fkom the prepared agar plate and inoculated in 2-10 ml of Luria
Bertani (LB) medium from Qiagen (1 L contains 10 grams NaC1, 10 grams tryptone, 5
grams yeast, and 800 ml ultrapure water). The final pH of the medium was adjusted to 7.0
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by adding NaOH, and HC1. The inoculated bacterial culture was incubated for
approximately 8 hours at 37OC and shaken at 3000 rpm in a Lab-Line incubator/shaker.
The starter culture was further diluted in 500 ml of selective LB medium for every 1 ml of
the starter culture. The above procedure was repeated this time for 12 - 16 hours, the
bacterial cells in LB medium were then harvested by centrifugation at 6000 x g at 4OC
using a Jouan, Model CT 4 22 centrifuge for approximately fifteen minutes and the
suspension was aspirated to obtain a pellet of bacterial cells. Purification of the resulting
pellet was performed using an Endotoxin Free kit from Qiagen. The bacterial pellet was
isolated and then resuspended in 10 ml of P1 Buffer. 1L of P1 contains 6.06 grams of Tris
base obtained from BioRad Companies, 3.72 grams Na2EDTA, and 100 mg RNase in
ultrapure water. The P1 buffer pH was adjusted to 8.0 using NaOH and HC1. Then 10 ml
of P2 buffer was added to the suspension and the resulting mixture was incubated at room
temperature for five minutes. 1 liter of P2 buffer contains 8 grams NaOH, 50 ml of 20%
SDS, and ultrapure water to a final volume of 1 liter. The resulting lysate was viscous and
contained contaminants; these impurities were removed via filtration through a qiagen
filter cartridge as instructed by the Qiagen supplier. The resulting eluate was collected in
pyrogen-free tubes provided by Qiagen. DNA was then precipitated using 10.5 ml of
isopropanol warmed to room temperature. The suspension was then mixed and centrifuged
at 15000 x g for approximately 30 minutes at 4OC (Jouan, Model CT 4 22) in a 50 ml
conical tube. The supernatant was removed and the resulting pellet was resuspended in 5
ml of ethanol. The resulting suspension was centrifuged again at 15000 x g for
approximately 10 minutes at 4OC, the suspension was aspirated and the resulting pellet was
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dried in air at room temperature. The pellet was then resuspended in 10 uL endotoxin
buffer-TE provided by Qiagen. 1 liter of TE buffer contains 5.84 grams NaC1, 1.21 grams
Tris base, and 0.37 grams Na2EDTA in ultrapure water to a final volume of 1 liter and pH
of 8.0.
2.5 Transfection of DNA into U266 Cells

In order to transfect the purified DNA, first U266 cell lines were adjusted to a
density of 3-5 x lo5 cells per ml and the density was confirmed using the coulter 22
particle counter from BeckmanCoulter (Fullerton, CA). Then 1 ug of DNA obtained from
the procedure in section 2.4 was prepared in 5 uL of ultrapure water. A 12 well plate from
Nunclon Surface Technologies was then filled with 1.5 ml of 1640 RPMI medium to each
well (see section 2.1 for contents). Next, U266 cells were centrifuged in a 50 ml conical
tube at 90 x g for 10 min in a Jouan, Model CT 4 22 centrifuge. The supernatant was
discarded and the resulting pellet of U266 cells were resuspended in Cell Line
Nucleofactor solution warmed to room temperature for approximately 20 minutes (Amaxa
Biosystems, Koln, Germany). Then the 1 ug of DNA in ultrapure water was added to the
prepared suspension of U266 cells in nucleofactor solution. Then 500 uL of suspension
consisting of cells and DNA was transferred to an amaxa cuvette and the sample was
placed into a Nucleofactor I system from Amaxa Biosystems (Koln, Germany). In this
case, we used nucleofactor technology; program V-01, which was preset by Amaxa
Biosystems. Once transfection of U266 cells was complete, 500 uL of pre-warmed 1640
RPMI culture medium was added to the cuvette and 500 uL of U266 cells in medium with
the new DNA was transferred to each well in the prepared plate. The 12 well plate was

30
incubated in a humidified incubator at a temperature of 37"C/ 5% C 0 2 for approximately
24 hours to ensure peak expression of the HRas gene. Expression of the gene was
confirmed using western blot analysis described in the later sections.

2.6 Reagents
UCN-0 1 was obtained from .the National Cancer Institute from Dr. Edward
Sausville. UCN-01 was dissolved in sterile DMSO and frozen under light-protective
conditions at -20°C (5). Lovastatin, Simvastatin, and Fluvastatin were purchased from
Calbiochem (San Diego, CA). The lovastatin, simvastatin, and fluvastatin were dissolved
in DMSO solution and stored at -80 OC in light-protective 1 ml microfuge tubes. Prior to
use appropriate dilutions were made for all experiments with sterile DMSO.

2.7 Experimental Format
Experiments were conducted using sterile 6 or 12 well plates obtained from
N~mclonSurface. For each experiment a volume of 1000 uL of logarithmically growing
cells at a density of approximately 3-5 x 10' cells/ml were added to each well. Cells were
then treated with UCN-0 1, Coenzyme reductase inhibitors (Calbiochem San Diego, CA) or
a combination of these and incubated at a temperature of 37 "C/ 5% C 0 2 at various time
intervals, generally intervals of 18 or 36 hours. After treatment, cells were subjected to
analysis to determine the extent of apoptosis using the following techniques.

2.8 Analysis of Apoptosis
The extent of apoptosis was first determined by viewing slides prepared by
cytospin in a Cyto-Tek centrifuge made by Sakura Finetek for 10 minutes at a speed of 5
rpm. The slides were encased in a filter cartridge with filters obtained from Cyto-Tek.
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Approximately 3000 uL of cells were used in each cartridge. Once centrifuged, the slides
were stained with Wright-Giemsa stain preparation (Sigma-Aldrich) and viewed under
light microscopy using a Zeiss Axiovert 40 x CFL microscope. "Scoring" was performed
by approximation of the number of cells that exhibited classical morphological features of
apoptosis including condensed nuclei and membrane damage (5). For each condition, 4 or
5 randomly selected fields were evaluated, containing at least 500 cells (5). To confirm the
results of morphological analysis, in some cases cells were also evaluated by
oligonucleosomal DNA fragmentation of total DNA as described later in this section.
2.9 Analysis of Mitochondrial Membrane Potential (AYm)
Mitochondrial membrane potential is used to characterize cellular apoptosis and
also cellular metabolism. The theory behind this assay is based on the electron transport
chain and changes in membrane potential. The electron transport system across the inner
mitochondria1 membrane creates a potential that is greatly reduced when the membrane is
damaged as it would occur if the cell was undergoing apoptosis. DiOC6 (3,3dihexyloxacarbocyanine iodide) is a cationic fluorescent dye. When there is accumulation
of DiOC6, it is an indication of living cells, whereas cells that do not take up the dye are
dead cells. In this procedure a volume of 300 to 4.00 uL of cells are transferred to a Falcon
brand polystyrene test tubes (12 x 75 mm). For every 100 uL of cells, 4 uL of DiOC6
prepared stock is added to each sample of cells. The prepared stock consists of 40 uL of
DiOC6 in 10 ml of PBS (Molecular Probes Inc., Eugene, OR). Once cells were treated
with DiOC6 dye, cells were incubated at 37OC/5% COz for 15 min and then analyzed by
flow cytometry using a Becton Dickinson FACScan and Cell Quest Pro Software version
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4.1 (Becton Dickinson, San Jose, CA). FacScan channels F1-1 and F1-2 that detect levels of
DiOC6 dye were adjusted to a range between 400 - 500 mV for F1-1 and 3 17 mV for F1-2
depending on the cell line used in each experiment. The percentage of cells that exhibit low
levels of DiOC6 uptake reflects loss of mitochondria1membrane potential and apoptosis.
2.10 Annexin V-FITC Analysis
In this assay, once apoptotic responses are confirmed using DiOC6, annexin V
analysis allows one to distinguish between early and late apoptosis. The early stage of
apoptosis is detected when the membrane phospholipid phosphatidylserine (PS) is
translocated from the inner leaflet of the plasma membrane to the outer leaflet and exposes
PS to the external environment. Annexin V is a calcium dependant phospho-lipid binding
protein and has a high affinity for PS. As described in the protocol, certain calcium and salt
concentrations are required to allow binding of annexin. In order to identify cells bound to
annexin, a fluorescent stain is used, specifically, fluorescein isothiocyanite (green
fluorescence). Each sample of cells is harvested at a density of 1x106,and transferred from
6 or 9 well plates (Nunclon Surface) to 1.5 ml microfuge tubes (ISC Bioexpress) and
centrifuged using a Labnet z cytospin (Herrnle) for five minutes at 15 rpm, and then
aspirated. The pellet of cells was washed with PBS (solution must be adjusted to a pH of
7.2 and autoclaved). 1 L of PBS contains 1.44 grams of Na2HP04*7H20,8 grams of NaC1,
0.24 grams of KH2P04, and 0.2 grams of KC1. Washes in PBS were repeated two or three
times, repeating the same procedure. PBS is then removed and the cell pellet was
resuspended in 500 ul of the annexin binding buffer (500 ml of binding buffer contains 10
mM of Hepes/NaOH that has a pH of 7.4, 140 mM of NaC1, and 2.5 mM CaC12). Finally,
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100 uL of the cells in binding buffer were transferred to 5 ml Falcon snap cap, polystyrene
tubes.
This was followed by the addition of 5 uL of annexin V-FITC (BD Biosciences) to
the Falcon tube along with 10 uL of propidium iodide stock (Sigma Aldrich). 20 ml of
propidium iodide stock for annexin V analysis contains 50 ug of propidium iodide in 20 ml
of l x PBS. The Falcon polystyrene tubes were incubated in a 37"C/5% C 0 2 incubator in
the dark for approximately 15 minutes. The final volume of samples in the polystyrene
tubes was adjusted to 500 uL by adding 400 uL of annexin binding buffer to the incubated
polystyrene tubes. For annexin V analysis, Facscan from Becton Dickinson was used along
with Cell Quest software version 4.1 x. The channels that were adjusted and correspond to
3
adjusted to 217-300 mV and 350-400 mV,
green and red fluorescence F1-1 and ~ 1 - were
respectively. F1-3 corresponds to propidium iodid stained cells; whereas, Annexin V stain
corresponds to F1- 1.

2.11 Cell Cycle Analysis
Changes in cell cycle may provide further insight into the mechanism involved in
apoptosis when cells are exposed to different reagents and can be measured either directly
or indirectly. In most of the direct assays, the time course for changes in DNA and
synthesis of DNA is measured. One direct method of identifying cell proliferation is
through incorporation of propidium iodide (Sigma Aldrich), a standard cytometric
fluorescence used to measure DNA content over a time course. Propidium Iodide was used
in annexin analysis above; however, in this case other ingredients were added to form
propidium iodide solution for cell cycle analysis. For each condition subjected to cell cycle
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analysis, 500 uL of cells (cell density 5 - 5.3 x 105/ml)were treated for approximately 8
hours with desired reagents (UCN-0 I, lovastatin, fluvastatin, and simvastatin either alone
or in combination). The cells were then pelleted at 1500 rpm, 4" C using the Jouan, Model
CT 4 22 and resuspended in 1.5 ml PBS followed by addition of 3 ml of 67% ethanol and
incubated at 4OC for an hour. After centrifugation, the samples were aspirated and the
pellet was resuspended in 1.0 ml propidium iodide solution (20 ml of propidiurn iodide or
propidium iodide solution contained 3.8 x 10" Na citrate to neutralize the acid, 0.5 mgln-11
RNAse, and 0.0 1 propidium iodide).
The resulting sample was analyzed by flow cytometry using the Becton Dickinson
Facscan and Cell Quest software as previously mentioned. The plot of F1-3 (channel
detecting red fluorescence) was set to approximately 217 - 300 mV. Cells stained with red
fluorescence indicate increase in DNA synthesis or changes in DNA compared to untreated
cells. For graphing the cell cycle data obtained from Cell Quest, curves were adjusted
manually using Modfit LT 2.0 software (Verity). In this analysis, data files were converted
to graphs showing peaks corresponding to S, G2/M, and GI phases of the cell cycle.

2.12 DNA Fragmentation
One major indication of apoptosis is the cleavage of chromosomal DNA at the
nucleosomal sites and is marked by fragmentation that occur at weights approximately 200
base pairs. Annexin V analysis, morphological analysis, and DNA fragmentation correlate
in showing apoptosis (5). For this assay cells were at a density of 20 x 1o5 cells/ml for each
sample, the cell density was confirmed using the coulter 22 particle analyzer. In this case,
a marker that marks every 100 bp is used (Invitrogen 10748-010). The cell samples were
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centrifuged at 1500 rpm for 10 minutes at 4" C (Jouan, Model CT 4 22) and the pellet was
resuspended in Gibco medium (see section 2.1 for contents). Then 450 uL of the lysis
buffer was added to the suspension (2 ml of lysis buffer consists of: 5 mM Tris-base from
BioRad, 20mM EDTA, 0.5 % TritonX-100 (with a pH of 8), and 100 uglml Proteinase K).
The lml solution containing cells and lysis buffer were vortexed and transferred to 1.5 ml
microfuge tubes (ISC Bioexpress USA). The samples were incubated in a water bath at 56"
C for approximately 18 hours. The samples were then centrifuged in an F-20 microrotor
(50,000 x g) for 45 minutes. This action separated the larger particles of the cell from the
cellular species of lower weight. The supernatant was carefully removed without touching
the pelleted cells at the bottom of the microfuge tube and the solution was transferred to a
new 1.5 microfuge tube. RNase A (Sigma-Aldrich) was then added to the existing solution
at a concentration of 200 ug RNase per 1 ml of lysis bufferlcells.
These samples were incubated for 3 hours at 37"C/5% C02. The 1.8% agarose gel
obtained from Gibco-BRL was mixed with a 500 ml volume of TBE buffer (1L of TBE
buffer contains 54 grams Tris-base, 27.5 grams boric acid, 20 ml0.5M EDTA (pH = 8.0)
in 1 liter of milli Q water). The prepared agarose was poured into a BioRad apparatus and
allowed to set to form a gel before electrophoresis using a 2 rnm tooth comb (BioRad) was
conducted. The gel was subjected to 120 volts until the purple band (DNA marker from
Invitrogen) migrated to a position 3-4 inches from the bottom of the BioRad apparatus.
2.13 Clonegenicity
To evaluate colony-forming ability following drug treatment, a soft agar cloning
assay was performed. Cells were briefly washed approximately three times with serum-free
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1640 RPMI medium (Gibco Life Technologies, see section 2.1 for contents).
Approximately 5000-50,000 cells/condition were used and the density was adjusted using
the Becton Dickinson Coulter 2 2 particle size analyzer. Then a 1% agar solution in
ultrapure water was prepared (agar fiom Invitrogen). A heat block from Fisher Scientific
was used to keep the agar warm (heated to 45OC) and prepared agar solution was aliquoted
to five 15 ml conical tubes. RPMI medium (Gibco Life Technologies) containing 20%
FBS was then added to five more separate conical tubes. Drug treatments were washed
from the treated cells using 1640 RPMI medium with 10% FBS (contents as described in
section 2.1). The coulter counterlparticle size analyzer to determine cell density and the
density was adjusted to 5000 - 50000 cells/ml according to the Becton Dickinson 22
Coulter counter. 1 ml of solution consisting of medium, agar and cells were added to a 12well plate (three wells per condition) with each well containing the same cell density. The
plates (Nunclon Surface Technologies) were placed in a 37"C/5% C02, fully humidified
incubator. Within the culture plates, 1 ml of ultrapure water was added between the wells
to ensure that the agar remained flexible. After 10 days of incubation visible colonies of
cells in agarose gel were scored using an Olympus Model CK inverted microscope (Model
AX70) and colony formation for each condition was calculated in relation to values
obtained for control cells (5).

2.14 Western Blot Analysis
Western blot analysis is generally used to view proteins according to weight.
Approximately 10 - 15 ml of heated cells at a density of 5-7 x 10' cells/ml were
transferred to a 15 ml conical tube and pelleted using a Jouan, Model CT 4 22 centrifbge at
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12,800 x g for five minutes at 4OC, the supernatant was removedldiscarded and the
remaining pellet was lysed by sonication (Misonix Model 2, Inc) in l x sample buffer (2 ml
of 1 x sample buffer is composed of the following: 62.5 mM Tris base (pH 6.8), 2% SDS,
50 rnM dithiothreitol, 10% glycerol, 0.1% bromphenol blue, and 5 mglml each
chymostatin, leupeptin, aprotinin, pepstatin, and soybean trypsin inhibitor (CLAPS), 1 mM
each sodium vanadate, sodium pyrophosphate (Na PPi)). Following sonication, the cells
lysated in sample buffer were transferred from the 15 ml tube conical tube to the 1.5 ml
micrifuge tubes and boiled for 5 min. The microfuge tubes containing the cells and sample
buffer were centrifuged at 12,800 for 5 min in a Hermle z cytospin from Z Net. Once
centrifuged, the cell samples were transferred to another 1.5 ml microfuge tube. Protein
concentration for each cell sample was quantified using Coomassie Protein Assay Reagent
(Pierce, Rockford, IL) (4). In this case, a Hitachi U-2000 spectrophotometer was used at a
wavelength of 595 nm in order to assure equal loading of protein during electrophoresis.
For measurements taken, 1 ml of ultrapure water was distributed to cuvettes along
with 1 ml of coomasie reagent, and 1 uL of sample. The absorbance exhibited by each
sample was then measured using the Hitachi spectrophotometer. One cuvette containing
only coomassie reagent and water was used for calibration of the instrument. Each sample
was gently inverted to mix the sample and measurements were automatically recorded in
uglul. Appropriate calculations were performed to ensure equal loading of cell samples
into the BioRad pre-made SDS gels with a 4-1 5% Tris-HC1 gradient and 15 uL volume
wells (catalog number 161-1158). The pre-made gels were place into a BioRad apparatus
and enough n m i n g buffer was added to cover the bottom half of the apparatus (2L of 5 x
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Running Buffer stock consisted of 188 grams of glycine, 30.4 grams of tris base, and 10
grams of SDS, and adjusted to a pH of 7.6. For making 2 L of running buffer, 400 ml of
stock was used and milli Q water was added to adjust the buffer volume to 2L). Finally,
samples were separated by SDS-Page electrophoresis at a voltage of 120 mV for
approximately for an hour and a half or until the straight purple band or marker (Invitrogen
10748-010) has reached approximately 3 inches from the bottom of the apparatus. The gel
samples were then transferred onto a 0.2 y nitrocellulose membrane (BioRad). For
transferring protein from the gel to a nitrocellulose membrane, cassettes (Fisher Scientific)
were soaked in transfer buffer (6 L transfer buffer contains 348 grams of glycine, 30.4
grams of tris base, and 3200 mL of methanol, and milli Q water filled to a volume of 6 L ,
and adjusted to a pH of 7.4). The sponge pad in the cassette was covered with filter squares
(Whatman 3M filter paper) before the gel was added on top of the filter. The combs and
bottom edge of the gel were removed before placing it on the filter and covering the gel
with the square nitrocellulose membrane. Rollers from Fisher Scientific were used to
remove air bubbles fiom the gap in between the gel and membrane. The cassette was
placed into the BioRad transfer box already containing transfer buffer. Once four cassettes
were added to the BioRad transfer box, transfer buffer was added to fill the box. The
transfer box was then set to receive 400 mA for two hours.
After transfer, cassettes were removed, the gel and filter discarded, and
nitrocellulose membranes were blocked with 5% milk (Carnation) in TBS-Tween 20. 2L of
10 x TBS-Tween 20 stock consisted of 24.2 grams Tris base, 80 grams NaC1, and 1 liter of
milli Q water. From stock to make a 2L solution of 1 x TBS-Tween 20 200 ml of the stock
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was used along with 2 ml of tween-20 and approximately 1.8 liters of ultrupure water to
achieve a final volume of 2 liters. The membranes were kept in the blocking solution at
room temperature for 1 hour. Then the blocking buffer was removed and the membrane
was probed with the desired primary antibody (see below for the specific primary
antibodies used). Before each primary antibody could be added to the membrane
appropriate dilutions of primary antibody were made in 5% BSA with 1 x TBS-Tween 20
(see above for TBS-Tween 20 contents). The membrane was incubated on a Lab-Line
shaker in the desired primary antibody/5% BSA in TBS-Tween 20 overnight at 4°C. The
blots were then washed twice in TBS-Tween 20 for 15 minutes and then incubated with a
1:2000 dilution of horseradish peroxidase-conjugated secondary antibody (anti-mouse or
rabbit) (Kirkegaard & Peny, Gaithersburg, MD) in 5% milk1TBS-Tween 20 at room
temperature for 1 hour. After washing twice in TBS-Tween 20 for 15 min, the proteins
were visualized via Western Blot Chemilurninescence Reagent (Perkinson and Elmer Life
Science Products, Boston, MA) (4). Finally, to ensure equal loading and transfer of
proteins, the blots were reprobed with antibodies against actin (Signal Transduction
Laboratories) or tubulin (Calbiochem).
The following antibodies were used as primary antibodies: phospho-p38 MAPK
(Thr180/Tyr182) antibody (1 :1000; rabbit polyclonal; NEB); phospho-JNK
(Thr183/Tyr185), JNK1, JNK2, phospho-Akt (Ser473), Akt; Cell Signaling Technology);
phospho-cdc2 (Tyrl5) antibody (1 :1000; rabbit polyclonal; Cell Signaling Technology);
anti-p2 1CipIWAF 1 (1500; mouse monoclonal; Transduction Laboratories,
Lexington,KY); anti-p27kipl (1 500; mouse monoclonal; PharMingen, San Diego, CA);
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antihuman Bcl-2 oncoprotein (1 :2000; mouse monoclonal; DAKO, Carpinteria, CA); Bax
(N-20; 1:2000; rabbit polyclonal; Santa Cruz Biotechnology Inc.); Bcl-xS/L (S-18; 1:500;
5 107 rabbit polyclonal; Santa Cruz Biotechnology Inc.). Antihuman/mouse XIAP (1 :500;
rabbit polyclonal; R&D System, Minneapolis, MN); anti-Caspase-3 (1 :1000; rabbit
polyclonal; PharMingen); cleaved-Caspase-3 (Mr 17,000) antibody (1:1000; rabbit
polyclonal; Cell Signaling Technology); anti-Caspase-9 (1 :1000; rabbit polyclonal;
PharMingen); anti-PARP (1 :2500; mouse monoclonal; Calbiochem); and cleaved PARP
(Mr 89,000) antibody (1 :1000; rabbit polyclonal; Cell Signaling Technology).
2.15 Analysis of Cytosolic Cytochrome C
Cells (2 -3 x1 o6 cells/ml) were centrifuged and washed in PBS then lysed by
incubating for 30 seconds in 2 mL of lysis buffer. The 2 ml of lysis buffer contains 75 mM
NaC1,8 mM Na2HP04, 1 mM NaH2P04, 1 mM EDTA, and 350 mglml digitonin. The
lysates were then centrifuged at 12,000 x g for 1 minute in a Cyto-Tek centrifuge, and the
supernatant was collected and added to an equal volume of 2x sample buffer. 1 ml of 2x
sample buffer contains 125 mM Tris base (pH 6.8), 2% SDS, 100 mM DTT, 10% glycerol.
The resulting protein samples were quantified using the same procedure described in the
previous section and separated by 15% SDS-PAGE, and subjected to western blot analysis
as described by the procedure in section 2.14. Anticytochrome c (mouse monoclonal;
PharMingen) was the primary antibody used at a dilution of 1:500.
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2.16 Statistical Analysis
For analysis of apoptosis (morphology and Annexin V), cell viability, and colony
forming ability, values represent the means h standard deviation for at least three separate
experiments performed in triplicate. Analysis of synergism was performed according to
Median Dose Effect analysis using Calcusyn and Prism software programs (Biosoft,
Ferguson, MO). Statistical analysis was done using Prism Pad Software, version 3
(Biosoft, Ferguson MO) using a student's t-test at an a priori significance level of p 5 0.05.

Results and Data Analysis
3.1 Co-administration of UCN-01 and Co-enzyme Reductase Inhibitors Induces a
Dramatic Apoptotic Response.
In the Figure 3.1, U937 and Jurkat cells were exposed to lovastatin and UCN-01
individually over a course of 18 hours. Following treatment over 18 hours, 400 uL of cells
were collected and treated to DiOC6 dye for membrane potential analysis. Apoptosis was
determined by the amount of DiOC6 taken up by the cell. For consistently varying doses
administered up to 150 nM of UCN-0 1, the degree of apoptosis shows a marked, but
gradual increase compared to the control cells (p 5 0.05). However, when the cells were
exposed to lovastatin (HMG CoenzymeA reductase inhibitor) combined with UCN-01 at
lower doses there is a significant increase (p 5 0.05) in the amount of apoptosis to 70 %
compared to cells exposed to UCN-01 alone. In Figure 3.2, there is a significant (p 5 0.05)
increase in apoptosis compared to the control cells when treated with gradually increasing
doses of lovastatin. However, cells treated with lovastatin combined with UCN-01 show a
significant (p 5 0.05) increase compared to cells treated with lovastatin alone. As
illustrated in Figure 3.3 for U937 (bottom left) and Jurkat cells (bottom right), combination
indexes are lower than 1.0 indicating synergistic interactions when administering LV and
UCN-01 at a constant ratio of 1000:5. The graphs below were created using Calcusyn
software.

Figure 3.1: Dose Response for U937 and Jurkat Cells (18 Hours)
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Figure 3.2: Dose Response for U937 and Jurkat Cells (18 Hours)
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Figure 3.3: Combination Index for Jurkat and U937 Cells
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3.2. UCN-01 Combined with Lovastatin Induces PARP Cleavage and Caspase
Activation.
The western blots in Figure 3.4 indicate that one possible mechanism by which
Lovastatin and UCN-01 induce apoptosis in leukemia cells is via the intrinsic pathway as
illustrated in the section I. Jurkat and U937 cells were treated with each condition as
indicated for 18 hours, cells were collected and pelleted and subjected to western blot
analysis as described in the materials and methods section. The data below demonstrates
that UCN-01 combined with the stains tested induces caspase 3,8, and 9 and PARP
cleavage. In these studies all three forms of statins were tested and varied slightly in their
potency. Once each western blot was probed with the primary antibody, all western blots
were washed in TBS-Tween 20 and re-probed with actin to ensure equal loading. To
differentiate between apoptosis and necrosis, further testing was done via annexin V
analysis (panel A) as indicated by the PI and annexin V stained cells in the upper and
lower right quadrants, respectively. Compared to the control, there is a marked shift in the

amount of cells to the upper and lower right quadrants stained with PI or annexin,
indicating early and late apoptosis.
Figure 3.4: Annexin and Western Blot Analysis
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3.3 UCN-OlIHMG-CoA Reductase Inhibitors Induces G 2 M Abrogation and Changes

Cell Morphology

The DNA staining illustrated in Figure 3.5A was done in order assess changes in
morphology and confirm apoptotic responses done during annexin staining. As mentioned
previously, in the methods section, the above cells were lysed and DNA was extracted
from the resulting supernatant then treated with sample buffer and separated via agarose
gel electrophoresis. The gel was stained with ethidium bromide and viewed under cannon
photomicroscopy. The graphs in Figure 3.5 Bydemonstate that there is a marked increase
of cells in the G2M phase of the cell cycle when leukemia cells (U937) are exposed to
UCN-01 or with HMG-CoerizymeA Yeductase inhibitors, individually. In addition, DNA
analysis demonstrates dramatic apoptotic responses due to DNA damage in cells exposed
to both reagents.

Figure 3.5: DNA Analysis and Cell Cycle
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3.4 UCN-01 and Lovastatin Induce Mitochondrid Membrane Damage and Induces

XIAP and Caspase 3 Cleavage.
In order to hrther assess the exact mechanism of apoptosis and determine cytosolic
distribution, leukemia cells were assessed via cytochrome c analysis (data not shown).
Cells overexpressing U937/CA-XIAP and U937/Empty vector cells were treated with
lovastatin (20 uM)IIJCN-01 (100 nM) for 18 hours and annexin V analysis was performed
on untreated cells and the combination of lovastatin and UCN-01. Figure 3.6 indicates the
release of cytochrome C and AIF expression when exposed to both lovastatin and UCN01. Compared with the XIAP/Empty vector cells, U937/CA- XtAP cells indicate a

significant (p 5 0.05) resistance to apoptosis when exposed to UCN-Ol/LV (18 hours).
Figure 3.6: Western Blots and Cytochrome C Analysis
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3.5 Lovastatin Blocks MEK/ERK Pathway Activated by UCN-01

In Figure 3.7, leukemia cells were subjected to western blot analysis. As indicated
above, ERK is activated by UCN-0 1 documented by the strong expression of phosphoE M when leukemia cells are exposed to UCN-0 1 alone and a marked increase in JNK

phosphorylation when combined with HMG CoA reductase inhibitors. However, when
lovastatin is administered (lane 3), p-ERK levels are dramatically decreased compared to
the amount of p-ERK expressed in the presence of UCN-0 1 alone. UCN-0 1, slightly
decreased p-cdc2 expression, whereas the combination of statinlUCN-0 1 dramatically
down-regulated of p-cdc2 phosphorylation. Finally, western blots were performed on two
RAS isoforms in order to assess the dominant isoform involved in RAS inhibition.
According to the blot, fluctuations in HRAS expression indicate that the unprocessed or
unmodified RAS (band 6) expression increases with the addition of lovastatin, simvastatin,
and fluvastatin. When lovastatin is administered in combination with UCN-01 these effects
are also present.
Figure 3.7 PI3KlAKT ad RAS/RAF/MEK/ERK Pathway
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3.6: Myeloma Cells Show Dramatic Apoptotic Response.

The cell lines below for 8226lSensitive cells and MM.1R Cells were subjected to
DiOC6 analysis to indicate the optimal synergistic response. Various cell lines were used
in the myeloma study to observe consistent protein expression and apoptotic response. The
8226lSensitive cell lines and MM.1R cell lines were treated with a corresponding control,
single, and combination of reagents for 18 and 24 hours. Figure 3.8 demonstrates a
significant (p 1 0.05) increase in apoptosis compared to the control cells when exposed to
UCN-01 alone in 8226lSensitive and 1R cells. In addition, Figure 3.8 illustrates a marked
(p 5 0.05) increase in apoptosis when cells are exposed to UCN-01 combined with

lovastatin compared to cells treated with UCN-0 1 or lovastatin alone. Figure 3.9
demonstrates a significant (p 5 0.05)-increasein apoptosis compared to the control cells
when exposed to lovastatin individually in 8226lSensitive and 1R cells. In addition, Figure
3.9 illustrates a marked (p 5 0.05) increase in apoptosis when cells are exposed to UCN-01
combined with lovastatin compared to cells treated with UCN-01 or lovastatin alone. U266
cells were exposed to a 24,36, and 48 hours in order to determine the optimal synergistic
response (data not shown). It was determined that the optimal time for treatment was 18
hours for MM. 1R and 8226 cell lines. The optimal synergistic response was achieved when
15 uM of lovastatin and 100 nM of UCN-0 1 were administered to 8226lSensitive cells and
MM. 1R cells. However, U226 cell lines were slightly more resistant and an optimal
synergistic response was demonstrated at 36 hours with 10uM of lovastatin and 100 nM of
UCN-0 1 (data not shown). For simvastatin, the same analysis was conducted as discussed
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above and the optimal response was achieved at a combination of doses of 20 uM of MK
and 100 nM of UCN-01 (data not shown).

Figure 3.8 Dose Response for MM.1R Cells and 8226 Cells (18 Hours)
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Figure 3.9 Dose Response for MM.1R and 8226 Cells (18 Hours)
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Figure 3.10: Combination Index for MM.1R and 8226 Cells (18 Hours)

3.7 Mitochondria1 Dysfunction and PARP Cleavage.
In Figure 3.1 1, the western blots demonstrate caspase 8 and caspase 9 cleavage
consistently throughout the myeloma cell line indicating that the mechanism involved in
the apoptotic response with UCN-0 llstatin combination causes mitochondria1 dysfunction
and involves the intrinsic pathway. In addition, PARP cleavage and XIAP cleavage also
indicate a similar molecular mechanism to that which occurs in leukemia cells. Annexin
analysis confirms apoptotic responses illustrated in preliminary DiOC6 analysis.

Figure 3.1 1 Mitochondria1 Dysfunction and Annexin V Analysis (8226 Cells)
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3.8 Inhibition of HRAS in Multiple Myeloma.

As demonstrated in Figure 3.12, inhibition of HRAS may be involved in the
apoptotic response with multiple myeloma cells as seen consistently in leukemia cells. In
Figure 3.12, 8226lSensitive cells indicated a very clear expression of the unprocessed
HRAS when exposed to the UCN-Ollstatin combination of reagents. As a result, M h e r
studies were done using U266lCA-HRAS cells in order to clearly assess that HRAS plays
a predominate role in RAS inhibition in multiple myeloma. Figure 3.12 B demonstrates
that U266lEmpty Vector cells conferred significant (p 5 0.05) sensitivity compared to
U266lCA-HRAS cells exposed to UCN-01 and lovastatin. Other small GTP proteins were
tested to determine consistencies in protein expression among leukemia and multiple
myeloma cells including Rho B and RAPA. Figure 3.12 A strongly indicates that UCNOlllovastatin inhibit RAS processing to a mechanism similar to that demonstrated by
leukemia cells.

Figure 3.12 RAS Expression in Multiple Myeloma (8226lSensitive)
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Discussion & Conclusion
4.1 Exposure of Leukemia Cells to Low Levels of UCN-01 and Lovastatin in
Combination Results in Dramatic Apoptotic Response.
In Figure 3.1 Jurkat and Leukemia cells exhibit minimal apoptotic responses when
exposed to either lovastatin or UCN-01 individually. In accordance with these results,
apoptosis varies from about 20% cell death to that of nearly 70% when exposed to the
combination. Apoptosis was not only assessed by mitochondria1 membrane potential, but
confirmed via Wright-Giemsa stain preparation and annexin V analysis. Mitochondrial
dysfunction indicated by DiOC6 was confirmed by cytochrome C analysis. Not only is
apoptosis dramatically increased, but cell proliferation is greatly reduced compared to the
control as verified by clonegenecity assays (data not shown). Compared to several clones
in the control group, the number of Jurkat and U937 clones decreased dramatically (nearly

65 %) when treated by HMG CoA-reductase inhibitors1UCN-01 reagents. The degree of
strength of each statin isoform varies slightly between the three forms tested with
lovastatin having the greatest effect followed by simvastatin and fluvastatin.

4.2 UCN-OlLovastatin Induces Apoptosis via the Mitochondrial Pathway
Interestingly, abrogation of the G2 checkpoint appears to occur preferentially in
cancer cells with defective p53 tumor suppressor function. UCN-01-induced G2 checkpoint
abrogation has previously been shown to occur through a Cdc2-dependent pathway
resulting in premature activation of this mitosis-promoting kinase in DNA-damaged cells.
The molecular mechanism resulting in Cdc2 activation and G2 checkpoint abrogation by
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UCN-01 are not known. Increased concentration of cytochrome C in the cytoplasm results
from the nucleation of a multiprotein complex known as the apoptosome. The apoptosome
is comprised of the Apaf-1 adapter protein, cytochrome C, dATP, and the aspartyl-directed
protease caspase 9. Cytochrome C binds to Apaf- 1, and this facilitates an interaction
between Apaf-1 and caspase 9. This interaction, in turn, activates the proteolytic activity of
Caspase 9.
4.3 Lovastatin Enhances UCN-01 Lethality Through Interruption of the
RAS/RAFMEK/ERK Pathway in Leukemia and Multiple Myeloma Cells
Because PI3WAKT represents a major downstream target of PUK, and has been
linked, through both indirect and direct mechanisms, to a wide variety of antiapoptotic
h c t i o n s , it is tempting to say that lovastatin promotes the lethal effects of CDK inhibitors
by blocking the activation of PUWAKT and one or more of its downstream targets,
thereby lowering the threshold for mitochoiidrial damage and apoptosis. However, in the
case of leukemia cells in this study it was found that while UCN-01 activated
phosphorylation of ERK, activation of ERK was blocked when UCN-01 was combined
with HMG CoenzyrneA reductase inhibitors and was primarily responsible for enhanced
apoptosis. The pathways downstream of RAS including PI3WAKT and MEKtERK have
repeatedly been shown to promote cell survival. This phenomenon has been confirmed by
previous studies in which protein kinase C and Chkl inhibitor UCN-01 interacts in a highly
synergistic manner with phannacologic reagents targeting the MEKIERK pathway in
human leukemia and myeloma cells. Other agents, such as the Hsp90 antagonist 17-AAG,
have also been shown to diminish UCN-01-induced ERK activation and potentiate
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apoptosis human leukemia cells, thereby mimicking the actions of pharmacologic MEK
inhibitors, such as PD98059 and U0126 (25) and HMG-CoA reductase inhibitors.
Interestingly, studies done with histone deacetylase inhibitors (HDACI) and alkyllysophospholipid perifosine were associated with an increase in reactive oxygen species
(ROS) production and implicated oxidative damage in HDACIIperifosine lethality.
Reactive oxygen species (ROS) have a major role in the mediation of cell damage. Several
defense mechanisms attempt to minimize the production and the action of harmful
oxidants. Such defense mechanisms include enzymes such as superoxide dismutase,
catalase, and glutathione peroxidase, as well as natural lipophilic and hydrophilic
antioxidants. Excessive ROS or inhibitiors of antioxidant pathways induce apoptosis.
Ceramide belongs to the class of sphingolipids, cholesterol and free fatty acids. Increased
levels of intracellular ceramides may either induce cell differentiation andlor apoptosis and
reduced cell proliferation, initiating pro-apoptotic signaling. The relationship between the
ceramide and ROS may vary with the cell type and inciting stimulus. For example,
although ceramide generates ROSYincreases in ROS formation can increase ceramide
levels in certain cells (26). More importantly, enforced activation of PI3WAKT or
MEWERK blocked HDACLIperifosine-mediated ceramide generation (26). Previous
studies have shown that ceramide and ROS can down-regulate PI3WAKT through a
caspase-dependent process. Conversely, ceramide blocks 3-phosphoinositide binding to the
pleckstrin homology domain of PI3WAKT. In addition, coadministration of HDACIs and
perifosine failed to increase ceramide levels in cells expressing constitutively active
PI3WAKT or MEWERK. Together, these findings show that inactivation of both
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MEKIERK and PI3WAKT is required for HDACIlperifosine-induced ceranlide production
and subsequent apoptosis. Although the above study demonstrates apoptotic mechanisms
involving other pathways, the similar phenomenon among these inhibitors is the ability to
interrupt the MEWERK and PI3UAKT activity to induce subsequent apoptosis.
4.4 Conclusions and Further Research

The above study suggests that RAS plays a particularly important role in preventing
apoptosis in leukemic cells experiencing CDK dysregulation. In addition, these and earlier
studies focusing on interactions between UCN-01 and MEK112 inhibitors provide further
evidence that leukemia cells are particularly sensitive when components of the cell cycle
and survival signaling events are simultaneously disrupted. In several studies
dysregulation of the PI3WAKT pathway is associated with transformation, and there is
extensive evidence that inhibitors of PI3UAKT can enhance the lethality of present
chemotherapeutics. As a result, researchers have searched for clinically relevant agents that
interrupt the PI3WAKT pathway and pathways that activate downstreams targets of
PI3WAKT. Specifically, the present studies suggest that HMG- CoA reductase inhibitors,
by blocking the PI3WAKT and MEWERK pathway may represent useful agents to
enhance the anti-tumor efficacy of agents like UCN-01. There is abundant evidence that
activation of the PI3UAKT pathway exerts antiapoptotic effects, although the
mechanism(s) by which this phenomenon occurs is not entirely understood and may vary
with cell type. Western blot analysis has indicated mitochondria1 dysfunction and
sensitivity to statin/UCN-01 reagents; however, the exact apoptotic mechanism is not clear.

Further studies are required to clarify the exact RAS isoform involved in PI3WAKT
regulation.
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